Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Pres. Research & Development

Chief Business - Strategy Off

Chief Executive Officer

Chief Development Officer

Chief Administrative Officer

Chief Financial Officer

President & CEO

Chief Operating Officer

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytidine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-07	Premium	bought	Premium	Premium	Premium	Pres. Research & Development
2024-02-06	Premium	bought	Premium	Premium	Premium	Pres. Research & Development
2024-02-01	Premium	bought	Premium	Premium	Premium	Chief Business - Strategy Off
2024-01-31	Premium	bought	Premium	Premium	Premium	Chief Business - Strategy Off
2024-01-30	Premium	bought	Premium	Premium	Premium	-
2024-01-30	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2024-01-01	Premium	acquired	Premium	Premium	Premium	Pres. Research & Development
2024-01-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Development Officer
2024-01-01	Premium	acquired	Premium	Premium	Premium	Chief Development Officer
2024-01-01	Premium	sold (taxes)	Premium	Premium	Premium	Pres. Research & Development
2024-01-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Business - Strategy Off
2024-01-01	Premium	acquired	Premium	Premium	Premium	Chief Business - Strategy Off
2024-01-01	Premium	acquired	Premium	Premium	Premium	Chief Administrative Officer
2024-01-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-01-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Administrative Officer
2023-11-21	Premium	sold	Premium	Premium	Premium	-
2023-10-12	Premium	acquired	Premium	Premium	Premium	Chief Administrative Officer
2023-10-12	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-10-12	Premium	acquired	Premium	Premium	Premium	-
2023-10-12	Premium	acquired	Premium	Premium	Premium	Pres. Research & Development
2023-10-12	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2023-10-12	Premium	acquired	Premium	Premium	Premium	Chief Business - Strategy Off
2023-10-10	Premium	acquired	Premium	Premium	Premium	Chief Business - Strategy Off

PCSA - Processa Pharmaceuticals, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for PCSA